唐氏综合征患者中的表皮生长因子受体突变型肺癌：病例报告及文献综述
Epidermal growth factor receptor-mutant lung cancer in Down syndrome: a case presentation and review of the literature.
作者信息
Li Xin, Xing Shijiang, Dong Qiumei
机构信息
Department of Medical Oncology, Xiaolan People's Hospital Affiliated to Southern Medical University, Zhongshan, China.
Department of Medical Oncology, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China.
出版信息
Oncotarget. 2017 Apr 25;8(33):55760-55765. doi: 10.18632/oncotarget.17406. eCollection 2017 Aug 15.
BACKGROUND
Solid tumors have a markedly decreased incidence in individuals with Down syndrome (DS), including lung cancers.
METHODS
The clinical presentation of epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) in DS was reported and literature on the subject reviewed.
RESULTS
In individuals with DS, the risk of lung cancer appears markedly lower. EGFR mutation and EGFR tyrosine kinase inhibitors (EGFR-TKIs) resistance also exist in DS with lung cancer.
CONCLUSIONS
Clinicians should consider EGFR mutation and EGFR-TKIs resistance in lung cancer patients with DS.
背景
唐氏综合征（DS）患者实体瘤的发病率显著降低，包括肺癌。
方法
报告了DS中表皮生长因子受体（EGFR）突变的非小细胞肺癌（NSCLC）的临床表现，并对该主题的文献进行了综述。
结果
在DS患者中，肺癌风险似乎明显较低。患有肺癌的DS患者中也存在EGFR突变和EGFR酪氨酸激酶抑制剂（EGFR-TKIs）耐药性。
结论
临床医生应考虑DS肺癌患者中的EGFR突变和EGFR-TKIs耐药性。
Zotero 插件